NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02029157,"A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)",https://clinicaltrials.gov/study/NCT02029157,JET-HCC,COMPLETED,"The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic chemotherapy regimen including sorafenib.",NO,Liver Cancer,DRUG: ARQ197|DRUG: Placebo,"Progression-free survival (PFS), Progression-free survival will be compared between ARQ 197 group and Placebo group, to prove the efficacy of ARQ 197 in the population., Estimated median of 8-12 weeks in PFS","Overall survival, The date of the events was followed every three months after the end of the treatments of the study drug., Estimated median of 24 weeks in overall survival",,"Kyowa Kirin Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,386,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",ARQ 197-009,2014-01,2017-08,2017-08,2014-01-07,,2017-10-09,"Cancer Centers in Japan, Tokyo, Japan",
